Time BioVentures

ActiveVenture Capital

Website LinkedIn

Updated: Jan 22, 2026 ·

Financial History

Total Raised

N/A

Valuation

N/A

Investments Made

Date	Company	Round	Lead Investor(s)	Co-Investor(s)
Apr 1, 2025	Phantom Neuro	$19.0M Series A	—	E1 Ventures, LionBird, Virginia Venture Partners
Jun 1, 2024	Better Health	$14.0M Series A	—	8VC, Afore Capital, Andreessen Horowitz, Caffeinated Capital, Cherry Ventures, Comcast Ventures, Construct Capital, Countdown Capital, Cubit Capital, Floodgate, Founders Fund, FPV Fund, General Catalyst, Kapor Capital, Lux Capital, Picus Capital, Ravelin Capital, Saga, Section 32, Stash Ventures, XYZ Venture Capital, Ash Rust, Ayo Omojola, Gokul Rajaram, Harry Hurst, Justin Mateen, Koen Koeppen, Rob Meyerson
Sep 1, 2022	Phantom Neuro	$6.0M Seed	—	E1 Ventures, LionBird, Virginia Venture Partners
Aug 1, 2022	Arena	$32.0M Series A	—	8VC, Alumni Ventures, Backstage Capital, CRV, Founders Fund, Friends & Family Capital, Great Oaks Venture Capital, Romero Rodrigues, Insight Partners, Luv Ventures, Northgate Capital, Y Combinator, Anthony Pompliano, Bill Ackman, David Petraeus, Immad Akhund
May 1, 2022	Strive Asset Management	$20.0M Seed	—	Access Industries, AirAngels, Daybreak Partners, Founders Fund, Human Capital, Lux Capital, Oak HC/FT, RallyCry Ventures, SoftBank Investment Advisers, Justin Rosenstein, Phil Libin
Mar 1, 2022	Phantom Neuro	$3.0M Seed	—	E1 Ventures, LionBird, Virginia Venture Partners
Oct 1, 2021	Better Health	$10.0M Series A	—	8VC, Afore Capital, Andreessen Horowitz, Caffeinated Capital, Cherry Ventures, Construct Capital, Countdown Capital, Cubit Capital, Dig Ventures, Floodgate, Founder Collective, Founders' Co-op, Founders Fund, FPV Fund, General Catalyst, Kapor Capital, Lux Capital, Meritech Capital Partners, Norwest Venture Partners, Jeff Richards, Picus Capital, Ravelin Capital, Saga, Section 32, Serena Ventures, SNR, Stash Ventures, Tiger Global Management, XYZ Venture Capital, Ash Rust, Ayo Omojola, Charlie Songhurst, Gokul Rajaram, Harry Hurst, Justin Mateen, Koen Koeppen, Rob Meyerson
Jul 1, 2021	Octane AI	$5.0M Venture Round	—	Daybreak Partners, Flex Capital, Founders Fund, Javelin Venture Partners, Justin Rosenstein, Michael Stoppelman
Nov 1, 2020	Nana Academy	$6.0M Seed	—	Kevin Hartz, Alt Capital, Bam Ventures, Collab Capital, E14 Fund, First Round Capital, Jett Fein, Initialized Capital, Kapor Capital, Left Lane Capital, Lerer Hippeau, Maveron, Next Play Ventures, Obvious Ventures, OODA Ventures, Pareto Holdings, Raine Ventures, Sequoia Capital, Social Capital, Spero Ventures, TechSquare Labs, Ulu Ventures, Unshackled Ventures, Velorum Capital, Vista Venture Partners, Volition Capital, WorkLife Ventures, Y Combinator, Yes VC, Anthony Pompliano, Bangaly Kaba, Baron Davis, David Lieb, Dylan Field, Eric Anschutz, Esther Dyson, Halle Tecco, Jared Sleeper, Jeff Hammerbacher, Jeremy Yap, John Henry, Justin Rosenstein, Kevin Lee, Kevin Weil, Nick Caldwell, Richard Rosenblatt
Aug 1, 2020	Octane AI	$4.0M Seed	—	bloom venture partners, Bullpen Capital, Daybreak Partners, Javelin Venture Partners, Reach Capital, Andrew Gluck, Justin Rosenstein, Konstantin von Unger, Larry Braitman, Lawrence Braitman, Phil Libin, Tom Blaisdell
May 1, 2020	Homestead	$2.0M Seed	—	75 & Sunny, Advisors Fund LLC, Bessemer Venture Partners, E14 Fund, Foundation Capital, Immeasurable, Invariantes Fund, Long Journey Ventures, OODA Ventures, Prefix Capital, Scribble Ventures, Social Capital, ThirdLove, Velorum Capital, Alison Pincus, Andy Bechtolsheim, Eric Anschutz, Esther Dyson, Jeff Hammerbacher, Jeremy Yap, Justin Rosenstein, Leonardo DiCaprio, Mark Pincus, Michael Staton, Ron Pragides, Scott Banister
Mar 1, 2020	H1.co	$13.0M Series A	—	Broadway Angels, E14 Fund, Felicis Ventures, FJ Labs, Flex Capital, Granatus Ventures, Menlo Ventures, OODA Ventures, Social Capital, Social Starts, Tiger Global Management, Underscore VC, Velorum Capital, Adam D'Angelo, Charlie Songhurst, Elliott Cohen, Eric Anschutz, Esther Dyson, Jeremy Yap, Justin Rosenstein, Marek Olszewski, Michael Staton, Russell Fradin, Russ Fradin
Apr 1, 2019	OccamzRazor	$5.0M Seed	—	Alt Capital, Collab Capital, E14 Fund, Felicis Ventures, Golden Ventures, Graph Ventures, Ground Up Ventures, GSV Acceleration, Indicator Ventures, Initialized Capital, Inventus Capital Partners, Kapor Capital, Maveron, Northside Ventures, Obvious Ventures, OODA Ventures, Pareto Holdings, Quiet Capital, Red Swan Ventures, RiverPark Ventures, Sequoia Capital, Social Capital, TechSquare Labs, Ulu Ventures, Unshackled Ventures, Velorum Capital, Vista Venture Partners, WorkLife Ventures, Y Combinator, Yes VC, Anthony Pompliano, Bangaly Kaba, Baron Davis, Ben Jabbawy, Brian Sugar, Eric Anschutz, Esther Dyson, Halle Tecco, Jeff Hammerbacher, Jeremy Yap, John Henry, Justin Rosenstein, Kevin Lee, Kevin Miller, Michael Staton, Nick Caldwell, Paul Hedrick, Preetha Parthasarathy, Rob Goldman
Sep 1, 2018	Tizeti	$3.0M Series A	—	8-Bit Capital, Angular Ventures, Battery Ventures, Boldstart Ventures, Bond, Caffeinated Capital, Catapult Capital, E14 Fund, Kleiner Perkins, Offline Ventures, OODA Ventures, Otherwise Fund, Sequoia Capital, Seven Seven Six, Social Capital, Threshold Ventures, Tribe Capital, Uncork Capital, Velorum Capital, Y Combinator, Aaron Harris, Alex Kayyal, Eoghan McCabe, Eric Anschutz, Esther Dyson, Frederic Kerrest, Hiten Shah, Jeff Hammerbacher, Jeremy Yap, Justin Rosenstein, Michael Staton, Pierre Valade, Sam Hickmann, Stewart Butterfield, Thibaud Elziere
May 1, 2017	Tizeti	$2.0M Seed	—	8-Bit Capital, Angular Ventures, Battery Ventures, Boldstart Ventures, Bond, Caffeinated Capital, Catapult Capital, E14 Fund, Kleiner Perkins, Offline Ventures, OODA Ventures, Otherwise Fund, Picus Capital, Sequoia Capital, Seven Seven Six, Social Capital, Threshold Ventures, Tribe Capital, Uncork Capital, Velorum Capital, Y Combinator, Aaron Harris, Alex Kayyal, Eoghan McCabe, Eric Anschutz, Esther Dyson, Frederic Kerrest, Hiten Shah, Jeff Hammerbacher, Jeremy Yap, Justin Rosenstein, Michael Staton, Pierre Valade, Sam Hickmann, Stewart Butterfield, Thibaud Elziere
Jan 1, 2017	Radish	$3.0M Seed	—	ACME Capital, Amasia, Amity Ventures, Blackbird Ventures Australia, Catapult Capital, Kevin Ding, DNX Ventures, E14 Fund, Founder Collective, Goodwater Capital, Mayfield, Menlo Ventures, NFX, NKM Capital, OODA Ventures, Polychain Capital, Quiet Capital, Social Capital, Tekton Ventures, Velorum Capital, Vouch Insurance, Bryan Meehan, Charlie Songhurst, Dylan Taylor, Emil Michael, Eric Anschutz, Esther Dyson, Jeff Hammerbacher, Justin Rosenstein, Liam Casey, Michael Staton, Moshe Lifschitz, Scott Belsky, Stuart Coulson
Nov 1, 2016	Octane AI	$2.0M Seed	—	Daybreak Partners, Reach Capital, Justin Rosenstein, Larry Braitman, Lawrence Braitman, Tom Blaisdell
Apr 1, 2013	Social Bicycles	$1.0M Seed	—	E14 Fund, OODA Ventures, Rose Tech Ventures, Social Capital, Social Starts, Velorum Capital, Eric Anschutz, Jeff Hammerbacher, Jeremy Yap, Justin Rosenstein, Michael Staton

Financial History

Total Raised

N/A

Valuation

N/A

Leadership Team

Key people at Time BioVentures.

Leadership Team

Key people at Time BioVentures.

Deep Dive

High-Level Overview

Time BioVentures is a Southern California–based venture capital firm specializing in early-stage investments in life sciences and healthcare technologies. Its mission is to finance visionary entrepreneurs developing game-changing healthcare innovations that extend patients' lives and improve health outcomes. The firm focuses on sectors such as therapeutics, diagnostics, digital health, and biotech, supporting startups that aim to transform healthcare delivery and patient care. Time BioVentures plays a significant role in the startup ecosystem by providing not only capital but also strategic guidance to accelerate the growth of pioneering healthcare companies[1][2][3][6].

Origin Story

Founded by a team including General Partner and Co-Founder D.A. Wallach, physician-scientist Dr. Tim Wright, and Senior Associate Ryan Moriarty, Time BioVentures leverages a blend of expertise in drug development, investment, and technology. The firm emerged from a shared vision to back early-stage healthcare innovators with the potential to bring breakthrough therapeutics and technologies to market. Over time, it has evolved to become a leading investor in life sciences, with a track record of supporting startups that have reached valuations exceeding $1 billion[5][6].

Core Differentiators

Unique Investment Model: Focus on early-stage life sciences and healthcare startups with a hands-on approach to capital and strategic support.
Network Strength: Access to a team with deep experience in drug development, biotech, and technology, including a physician-scientist and creative business leaders.
Track Record: Proven success with sixteen portfolio companies achieving valuations over $1 billion.
Operating Support: Active involvement in portfolio management, leveraging expertise in therapeutics, diagnostics, and digital health to guide startups through critical growth phases[5][6].

Role in the Broader Tech Landscape

Time BioVentures rides the wave of increasing convergence between biotechnology, digital health, and advanced therapeutics. The timing is critical as healthcare innovation accelerates with advances in gene therapy, AI-driven diagnostics, and personalized medicine. Market forces such as rising healthcare demands, regulatory support for innovation, and growing investment interest in biotech create a favorable environment. The firm influences the broader ecosystem by enabling early-stage companies to translate scientific breakthroughs into viable commercial products, thus driving forward the future of healthcare[1][2].

Quick Take & Future Outlook

Looking ahead, Time BioVentures is poised to continue expanding its portfolio in cutting-edge healthcare technologies, potentially increasing focus on AI integration and next-generation therapeutics. Trends such as precision medicine, digital health platforms, and novel drug modalities will likely shape their investment strategy. As healthcare challenges grow globally, Time BioVentures’ influence is expected to deepen, helping to bring transformative solutions to market faster and improving patient outcomes worldwide[2][5]. Their commitment to giving patients "more of life’s most valuable asset: time" remains a compelling guiding principle for their future trajectory.

Sources

High-Level Overview

Origin Story

Core Differentiators

Unique Investment Model: Focus on early-stage life sciences and healthcare startups with a hands-on approach to capital and strategic support.
Network Strength: Access to a team with deep experience in drug development, biotech, and technology, including a physician-scientist and creative business leaders.
Track Record: Proven success with sixteen portfolio companies achieving valuations over $1 billion.
Operating Support: Active involvement in portfolio management, leveraging expertise in therapeutics, diagnostics, and digital health to guide startups through critical growth phases[5][6].